CD33 - Revision history

John at 13:43, 17 July 2023

2023-07-17T13:43:08Z

← Older revision		Revision as of 15:43, 17 July 2023
Line 26:		Line 26:
	*Overall around 80-90% of AML cases express CD33; although the marker tends not to be expressed the least mmature forms, as well as those with erythroid or megakaryocytic differentiation. High CD33 expression may correlate with ''NPM1'' mutation		*Overall around 80-90% of AML cases express CD33; although the marker tends not to be expressed the least mmature forms, as well as those with erythroid or megakaryocytic differentiation. High CD33 expression may correlate with ''NPM1'' mutation
	*Approximately 10% of B or T lymphoblastic leukaemias and lymphomas may aberrantly express CD33 as well as up to 25% of myeloma cases		*Approximately 10% of B or T lymphoblastic leukaemias and lymphomas may aberrantly express CD33 as well as up to 25% of myeloma cases
	*CD33 not expressed by mature cells of erythroid, platelet, B-cells T-cells or NK-cell lineage		*CD33 is not expressed by mature cells of erythroid, platelet, B-cells T-cells or NK-cell lineage
	*CD33 is expressed throughout myeloid maturation and is found on mature myeloid cells, though less strongly on cells of monocytic lineage		*CD33 is expressed throughout myeloid maturation and is found on mature myeloid cells, though less strongly on cells of monocytic lineage

John at 19:42, 4 July 2023

2023-07-04T19:42:53Z

← Older revision		Revision as of 21:42, 4 July 2023
Line 70:		Line 70:
	\|-		\|-
	!colspan="8"\|'''Expression in mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%

John at 11:09, 3 July 2023

2023-07-03T11:09:40Z

← Older revision		Revision as of 13:09, 3 July 2023
Line 49:		Line 49:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|~~<span style="font-size:100%">~~'''Expression in primitive cell types'''</font>		!colspan="8"\|'''Expression in primitive cell types'''</font>
	\|-		\|- <span style="font-size:70%">
	! AML !! CMML !! B ALL !! ~~Burkitt~~ \|\| T ALL !! ETP ALL ~~<'''[[ETP ALL\|I]]'''>~~ !! ~~MPAL <'''[[~~MPAL~~\|I]]'''>~~ \|\| ~~Hgns~~ <~~'''[[Hgns\|I]]'''~~>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%*		\|style="width: 12.5%; background: #004466; color:white"\|80-100%*
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John: Created page with "
:'''Summary''' :CD33 a useful marker contributing to the diagnosis of AML, but is less specific than myeloperoxidase and may be less sensitive than CD117. :The molecule is expressed by normal maturing myeloid cells, and there is recognised aberrant expression by primitive lymphoid cells (10-20%).
'..."

2023-05-16T08:24:32Z

Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :'''Summary''' :CD33 a useful marker contributing to the diagnosis of AML, but is less specific than myeloperoxidase and may be less sensitive than CD117. :The molecule is expressed by normal maturing myeloid cells, and there is recognised aberrant expression by primitive lymphoid cells (10-20%). </div> '..."

New page

<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">

:'''Summary'''

:CD33 a useful marker contributing to the diagnosis of AML, but is less specific than myeloperoxidase and may be less sensitive than CD117.
:The molecule is expressed by normal maturing myeloid cells, and there is recognised aberrant expression by primitive lymphoid cells (10-20%).

</div>

'''Normal expression and function'''

CD33 a transmembrane receptor that is thought to function as an inhibitory protein supressing signals of the innate immune system. It is strongly expressed on multi-lineage hematopoietic progenitors and also on myelomonocytic precursors (although generally less strongly than CD13). Expression is absent from the more primitive pluripotent hematopoietic stem cells and CD33 is down-regulated on mature granulocytes, human mast cells, and blood basophils.

'''Diagnostic role'''

*Overall around 80-90% of AML cases express CD33; although the marker tends not to be expressed the least mmature forms, as well as those with erythroid or megakaryocytic differentiation. High CD33 expression may correlate with ''NPM1'' mutation
*Approximately 10% of B or T lymphoblastic leukaemias and lymphomas may aberrantly express CD33 as well as up to 25% of myeloma cases
*CD33 not expressed by mature cells of erythroid, platelet, B-cells T-cells or NK-cell lineage
*CD33 is expressed throughout myeloid maturation and is found on mature myeloid cells, though less strongly on cells of monocytic lineage

'''Other relevant information:'''

CD33 has received particular attention for its role as the molecular target of antibody-based treatment strategies in the therapy of AML.

----

'''''SUMMARY TABLES'''''

'''Note''' The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click [[Key to marker expression table|here]]. For further information about a particular disease state click <'''I'''> adjacent to the condition name

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in primitive cell types'''
|-
! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
|-
|style="width: 12.5%; background: #004466; color:white"|80-100%*
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 12.5%; background:#004466; color:white"|80-100%***
|-
|}

'''Notes:''' ''*'' most cases of AML express this marker although it can be absent (see notes above) ''**'' CD33 is commonly expressed in ALL (particularly B-ALL), but in the correct context can also contribute to detection of MPAL or ETP-ALL, ''***'' Haematogones frequently express CD33 

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|-
|}

'''Notes:''' CD33 is occasionally expressed in mature lymphoid malignancies more frequently in b cell types

{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''CD13 expression: mature T cell neoplasms'''
|-
! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|-
|}

'''Notes:''' There is limited published evidence, but reports suggest expression of CD33 is uncommon in mature T cell malignancy

----